(Adnkronos) – In patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL), regardless of age, an induction and consolidation strategy without chemotherapy, combining targeted therapy with a third-generation tyrosine kinase inhibitor (TKI) (ponatinib) and immunotherapy with a bispecific antibody (blinatumomab), is superior to standard treatment (TKI + chemotherapy), while reducing side effects. These are the results of the phase 3 Gimema All2820 study, coordinated by Sabina Chiaretti, Professor of Hematology at Sapienza University of Rome, Robin Foà, Emeritus Professor of Hematology at Sapienza University of Rome, and promoted by Fondazione Gimema – Franco Mandelli Ets, recently published in the ‘New England Journal of Medicine’. It is the latest stage in an entirely Italian story, which began in 2000 with the Gimema Lal0201 study, which radically changed the first-line treatment of adult patients with Ph+ ALL.
In the Gimema All2820 trial, from September 2021 to January 2025 – a note reports – 236 adult patients, aged between 24 and 82, with newly diagnosed Ph+ ALL were involved in the trial: 158 received the new experimental therapy and 78 received the standard therapy. The experimental therapy involved the use of TKI ponatinib, followed by 2 to 5 cycles of intravenous blinatumomab; the standard therapy involved TKI imatinib with chemotherapy. The main objective of the trial was to demonstrate that the combination of TKI and immunotherapy was more effective than standard treatment in controlling the disease over time. To evaluate this, researchers considered event-free survival (EFS) as the main indicator, a measure that takes into account not only patient survival, but also treatment response (hematological response), the possible persistence of the disease at a molecular level (molecular response), and the occurrence of unfavorable events such as relapse. Particular attention was paid to molecular response, which allows the detection of even extremely small quantities of residual disease, not identifiable with traditional tests, and which represents an important indicator of the depth of the therapeutic response.
The results demonstrated the superiority of the new chemotherapy-free therapeutic strategy. Two years after the start of treatment, 86% of patients treated with ponatinib and blinatumomab had not experienced any of the possible unfavorable events considered in the study, compared to 67% of patients treated with standard therapy. A significant difference, which represents the main result of the trial. At the end of the first phase of treatment (induction), 94% of patients in the experimental group had achieved complete hematological remission, compared to 79% in the standard group.
The new combination – the note specifies – also allowed for deeper responses to therapy after the subsequent consolidation phase with blinatumomab. In fact, molecular response was achieved by 71% of patients treated without chemotherapy, compared to 49% of those undergoing traditional treatment. This means that, in a significantly higher percentage of patients, the disease had become undetectable or present only in minimal traces through highly sensitive molecular tests. The results were also favorable for other clinical indicators. At two years, overall survival was 90% in the experimental group compared to 85% in the standard group, while the cumulative probability of relapse was 5% and 13% respectively.
Ph+ ALL is characterized by a genetic alteration due to a chromosomal translocation, i.e., an exchange of genetic material between two chromosomes. This phenomenon leads to the fusion of the Bcr and Abl1 genes, giving rise to the Bcr-Abl1 fusion gene, which produces an abnormal protein whose activity promotes uncontrolled cell proliferation and contributes to the development of the disease. For a long time, chemotherapy and allogeneic hematopoietic stem cell transplantation represented the pillars of treatment for this blood cancer. Starting in the early 2000s, the introduction of TKIs marked a decisive turning point, significantly improving therapeutic results and paving the way for increasingly targeted and less intensive treatment strategies. In this journey, the Gimema group played a pioneering role, initiating one of the first protocols based on the use of imatinib without chemotherapy in the induction phase in 2000. Since then, subsequent Gimema studies have progressively explored the use of first, second, and third-generation TKIs, contributing to the development of therapeutic approaches capable of reducing the reliance on conventional chemotherapy. Today, the association between targeted therapy and immunotherapy represents a further and important step forward. This strategy – the note continues – is profoundly transforming the clinical management and treatment prospects of Ph+ ALL, a form of leukemia once associated with a particularly unfavorable prognosis.
“The value of the Gimema All2820 study lies not only in demonstrating that the combination of targeted therapy and immunotherapy is superior to standard treatment – Foà points out – but in providing solid evidence to support a possible paradigm shift in the treatment of adult Ph+ ALL. Giving up conventional chemotherapy, without compromising the effectiveness of treatments and, indeed, improving their outcomes, is a result of great importance. And it is also a demonstration of the value of independent clinical research, capable of testing new therapeutic strategies and translating scientific progress into concrete benefits for patients.”